← Eichor
Condition: Cutaneous Metastasis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cutaneous Metastasis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Krystal Biotech, Inc. · NCT05970497Primary vs Secondary Closure of Tracheo-cutaneous Fistulas
NA · 1 location(s) · Université de Sherbrooke · NCT04647968BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1/Phase 2 · 4 location(s) · OncoResponse, Inc. · NCT06090266Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627698A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/Phase 2 · 20 location(s) · Hummingbird Bioscience · NCT05910827Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
Phase 1 · 1 location(s) · Nicholas Gulati · NCT05481658Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
NA · 1 location(s) · Alpha Tau Medical LTD. · NCT03889899Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma
NA · 1 location(s) · Institute of Oncology Ljubljana · NCT07404605A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05859074Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients
Phase 2 · 6 location(s) · National Cancer Center, Japan · NCT06673628Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Pat
Phase 2 · 1 location(s) · EuroCityClinic LLC · NCT07130032Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma
NA · 5 location(s) · Azienda Ospedaliera di Perugia · NCT07050940Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Phase N/A · 1 location(s) · Mayo Clinic · NCT06075524Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune Syst
Phase 2 · 38 location(s) · National Cancer Institute (NCI) · NCT07042295Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metasta
Phase 1/Phase 2 · 26 location(s) · National Cancer Institute (NCI) · NCT05896839Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
Phase 1 · 5 location(s) · MonTa Biosciences ApS · NCT048554353'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresect
NA · 3 location(s) · Alpha Tau Medical LTD. · NCT05047094MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 · 2 location(s) · Memgen, Inc. · NCT05076760Intratumoral N17350 in Advanced Solid Tumors
Phase 1/Phase 2 · 8 location(s) · Onchilles Pharma Inc · NCT07339176Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
NA · 1 location(s) · Alpha Tau Medical LTD. · NCT04534127Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma
NA · 1 location(s) · David Palma · NCT07337161Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spre
Phase 3 · 192 location(s) · National Cancer Institute (NCI) · NCT06589804Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Phase 1 · 5 location(s) · Ankyra Therapeutics, Inc · NCT06171750A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic So
Phase 2 · 119 location(s) · Daiichi Sankyo · NCT06330064Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Phase 1/Phase 2 · 15 location(s) · IDEAYA Biosciences · NCT03947385A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors
Phase 1 · 4 location(s) · Beyond Air Inc. · NCT05351502
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.